Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors.
10.3760/cma.j.cn112150-20210601-00528
- Author:
Li JIANG
1
;
Kui XIAO
2
;
Hai LONG
1
Author Information
1. Department of Dermatology, the Second Xiangya Hospital of Central South University, Institute of Dermatology and Venereology of Central South University, Hunan Clinical Medicine Research Center for Major Skin Diseases and Skin Health, Changsha 410011, China.
2. Department of Respiratory and Critical Care Medicine, the Second Xiangya Hospital of Central South University, Institute of Respiratory Diseases of Central South University, Changsha 410011, China.
- Publication Type:Review
- MeSH:
Antibodies, Monoclonal/adverse effects*;
Antineoplastic Agents/therapeutic use*;
ErbB Receptors/therapeutic use*;
Humans;
Neoplasms/drug therapy*;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Preventive Medicine
2022;56(1):87-94
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor (EGFR) signaling is aberrantly overexpressed in many solid malignancies, making it an important target for anti-cancer biologic agents. Among them, epidermal growth factor receptor inhibitors (EGFRIs), which have been widely used in clinical practice, include anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors. A proportion of patients treated with EGFRIs develop specific, dose-dependent skin toxicity such as papulopustular rash, paronychia, xerosis and itch. These side effects can cause physical and psychosocial discomfort that may result in dose reduction, discontinuance, or replacement of the current EGFRIs treatment. Correct diagnosis and treatment of these skin and mucosal adverse effects associated with EGFRIs is of great significance for the tertiary prevention of malignant tumors. A review on EGFRI-related mucocutaneous adverse reactions is presented here, focusing on the pathogenesis, the various clinical manifestations, the strategies for prevention and treatment of these conditions.
